NCT04369365View on ClinicalTrials.gov

A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions
COVID
Interventions
DRUG

Azithromycin 500 milligram (mg) oral Tablet

weekly oral use

DRUG

Placebo

weekly oral use

Trial Locations (1)

1090

AKH Vienna, Department for Internal Medicine I, Oncology, Vienna

All Listed Sponsors
lead

Prof. Dr. Matthias Preusser

OTHER

NCT04369365 - A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic | Biotech Hunter | Biotech Hunter